Loading...
Loading...
Among the 7 tracked institutional investors we monitor, BBOT (BRIDGEBIO ONCOLOGY THERAPEUT) is held with a combined value of $58.70M across 6,242,586 shares. The largest holder is CITADEL ADVISORS LLC with a position worth $22.63M (0.00% of their portfolio). VANGUARD GROUP INC opened a new position in the most recent quarter. 4 funds increased their holdings. 1 fund reduced its position.
Total Institutional Value
$58.70M
Total Shares Held
6,242,586
Institutional Holders
7
| # | Fund | Value↓ | Portfolio % | Change |
|---|---|---|---|---|
| 1 | CITADEL ADVISORS LLC | $22.63M | 0.00% | -0.1% |
| 2 | BlackRock, Inc. | $18.69M | 0.00% | +0.2% |
| 3 | VANGUARD GROUP INC | $9.90M | 0.00% | New |
| 4 | MILLENNIUM MANAGEMENT LLC | $2.38M | 0.00% | +10.2% |
| 5 | FMR LLC | $2.15M | 0.00% | - |
| 6 | STATE STREET CORP | $2.03M | 0.00% | +3.7% |
| 7 | RENAISSANCE TECHNOLOGIES LLC | $912.00K | 0.00% | +37.1% |
As of the latest SEC 13F filings, CITADEL ADVISORS LLC is the largest institutional holder of BBOT with a position worth $22.63M, representing 0.00% of their portfolio. In total, 7 institutional investors hold BBOT with a combined value of $58.70M.
In the most recent quarter, 1 fund opened a new position in BBOT. Additionally, 4 increased their holdings and 1 reduced their positions.
Institutional investors hold $58.70M worth of BBOT stock across 7 positions. The largest institutional holder is CITADEL ADVISORS LLC with $22.63M in holdings.
A 13F filing is a quarterly report required by the SEC from institutional investment managers with over $100 million in assets. It discloses their holdings in U.S. equities. For BBOT, these filings reveal which major funds are accumulating or reducing positions, providing insights into institutional sentiment.
Get notified when hedge funds change their BBOT positions.